JP2023544173A5 - - Google Patents

Info

Publication number
JP2023544173A5
JP2023544173A5 JP2023520080A JP2023520080A JP2023544173A5 JP 2023544173 A5 JP2023544173 A5 JP 2023544173A5 JP 2023520080 A JP2023520080 A JP 2023520080A JP 2023520080 A JP2023520080 A JP 2023520080A JP 2023544173 A5 JP2023544173 A5 JP 2023544173A5
Authority
JP
Japan
Prior art keywords
cancer
salt
fibrosis
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023520080A
Other languages
English (en)
Japanese (ja)
Other versions
JP7865951B2 (ja
JP2023544173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052898 external-priority patent/WO2022072648A1/en
Publication of JP2023544173A publication Critical patent/JP2023544173A/ja
Publication of JP2023544173A5 publication Critical patent/JP2023544173A5/ja
Application granted granted Critical
Publication of JP7865951B2 publication Critical patent/JP7865951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023520080A 2020-10-02 2021-09-30 転写活性化タンパク質のイミダゾピペラジン阻害剤 Active JP7865951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086728P 2020-10-02 2020-10-02
US63/086,728 2020-10-02
PCT/US2021/052898 WO2022072648A1 (en) 2020-10-02 2021-09-30 Imidazopiperazine inhibitors of transcription activating proteins

Publications (3)

Publication Number Publication Date
JP2023544173A JP2023544173A (ja) 2023-10-20
JP2023544173A5 true JP2023544173A5 (cg-RX-API-DMAC7.html) 2024-10-07
JP7865951B2 JP7865951B2 (ja) 2026-05-26

Family

ID=80950902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520080A Active JP7865951B2 (ja) 2020-10-02 2021-09-30 転写活性化タンパク質のイミダゾピペラジン阻害剤

Country Status (14)

Country Link
US (2) US12559497B2 (cg-RX-API-DMAC7.html)
EP (1) EP4221709B1 (cg-RX-API-DMAC7.html)
JP (1) JP7865951B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230080441A (cg-RX-API-DMAC7.html)
CN (1) CN116261454A (cg-RX-API-DMAC7.html)
AU (1) AU2021355480B2 (cg-RX-API-DMAC7.html)
CA (1) CA3193745A1 (cg-RX-API-DMAC7.html)
DK (1) DK4221709T3 (cg-RX-API-DMAC7.html)
ES (1) ES3068299T3 (cg-RX-API-DMAC7.html)
IL (1) IL301707A (cg-RX-API-DMAC7.html)
MX (1) MX2023003785A (cg-RX-API-DMAC7.html)
PL (1) PL4221709T3 (cg-RX-API-DMAC7.html)
PT (1) PT4221709T (cg-RX-API-DMAC7.html)
WO (1) WO2022072648A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
AU2024331409A1 (en) * 2023-08-30 2026-03-12 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as cbp/p300 degraders and uses thereof
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270143T3 (es) 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2007139992A2 (en) 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AU2007337659A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EA201000046A1 (ru) 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2013050446A1 (en) 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
CN103087067A (zh) 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物,以及它们的用途
WO2014062548A1 (en) 2012-10-18 2014-04-24 Bristol-Myers Squibb Company Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CN107108512B (zh) 2014-10-10 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3632915A1 (en) * 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제

Similar Documents

Publication Publication Date Title
JP2018515490A5 (cg-RX-API-DMAC7.html)
RU2020131507A (ru) Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
JP5269762B2 (ja) Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
CN115626935B (zh) 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
JP2019516759A5 (cg-RX-API-DMAC7.html)
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
KR20210018291A (ko) 항암 핵 호르몬 수용체-표적화 화합물
JP2023544732A5 (cg-RX-API-DMAC7.html)
JP2020517637A (ja) Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6019126B2 (ja) 有機ニトロチオエーテル化合物およびその医療用途
JP2019513743A (ja) インドールアミン 2,3−ジオキシゲナーゼ阻害剤、その製造方法及び応用
JP2017510641A5 (cg-RX-API-DMAC7.html)
JP6842474B2 (ja) ステロイド系化合物、当該化合物を含む組成物及びその使用
JP2021505641A (ja) PPAR−γ調節薬としての新規なベンズアミド誘導体
JP2018501287A5 (cg-RX-API-DMAC7.html)
IL298966A (en) Bicyclic compound and application thereof
JP7691974B2 (ja) アセチル補酵素aシンテターゼ短鎖2(acss2)の小分子阻害剤
CN111303133A (zh) 降解ezh2蛋白的小分子化合物
WO2025209490A1 (en) Macrocyclic compound, preparation methods and medicinal uses thereof
JP2023544173A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
US20210196724A1 (en) Biaryl compositions and methods for modulating a kinase cascade
TW200932217A (en) Substituted hydantoins
TW201245183A (en) Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
CN106432209A (zh) Lumacaftor的新晶型及其制备方法
JP2023544732A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤